Research Grade Istiratumab (DHC29907)

Catalog No.

DHC29907

Expression system

Mammalian Cells

Species reactivity

Human

Host species

Human

Isotype

IgG1-kappa-[scFv]2

Clonality

Monoclonal

Target

CD221, Insulin-like growth factor 1 receptor, IGF1R, Insulin-like growth factor I receptor, IGF-I receptor, ERBB3, HER3, Proto-oncogene-like protein c-ErbB-3, Tyrosine kinase-type cell surface receptor HER3, Receptor tyrosine-protein kinase erbB-3

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P08069 & P21860

Applications

Research Grade Biosimilar

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Alternative Names

Bispecific, MM-005, MM-141, CAS: 1509928-04-4

Clone ID

Istiratumab

Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE), PMID: 31912800

Corrigendum to 'Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE)': Annals of Oncology, Volume 31, Issue 1, 2020, Pages 79-87, PMID: 32507672

Dual targeting of IGF-1R and ErbB3 as a potential therapeutic regimen for ovarian cancer, PMID: 31728045

Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer, PMID: 29549161

MM-141, an IGF-IR- and ErbB3-directed bispecific antibody, overcomes network adaptations that limit activity of IGF-IR inhibitors, PMID: 24282274

Document Download

Research Grade Istiratumab.pdf